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The amygdala is a key structure in a limbic circuit involved in the rapid and unconscious processing of facial emotions. Increased amygdala
reactivity has been discussed in the context of major depression. Recent studies reported that amygdala activity during conscious
emotion processing is modulated by a functional polymorphism in the serotonin transporter gene (5-HTTLPR) in healthy subjects. In the
present study, amygdala reactivity to displays of emotional faces was measured by means of fMRI at 3T in 35 patients with major
depression and 32 healthy controls. Conscious awareness of the emotional stimuli was prevented via backward-masking to investigate
automatic emotion processing. All subjects were genotyped for the 5-HTTLPR polymorphism. Risk allele carriers (S or LG) demonstrated
increased amygdala reactivity to masked emotional faces, which in turn was significantly correlated with life-time psychiatric hospitalization
as an index of chronicity. This might indicate that genetic variations of the serotonin transporter could increase the risk for depression
chronification via altering limbic neural activity on a preattentive level of emotion processing.
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Converging evidence suggests that the serotonin system
plays a critical role in the pathophysiology of major
depression (Wong and Licinio, 2001). During the last
decade, genetic variations in the serotonin system have been
discovered that might constitute susceptibility factors for
the development of depression. The serotonin transporter
(5-HTT) facilitates re-uptake of serotonin from the synaptic
cleft and is the target of most antidepressant drugs. In the
promoter region of the serotonin transporter gene, mapping
to chromosome 17q11.1-12, a functional variable repeat
sequence polymorphism (5-HTTLPR) resulting in a short
(S) and a long (L) variant has been identified (Lesch et al,
1996). It was repeatedly found that S allele carriers are more
prone to the depressogenic effect of stressful life events than
homozygotes for the L allele (Caspi et al, 2003; Kendler et al,
2005). Furthermore, 5-HTTLPR ‘risk alleles’ were reported
to be associated with depression severity (Zalsman et al,
2006) and reduced therapy response (Smits et al, 2004).
However, other studies failed to find associations of 5-
HTTLPR with major depression (Willis-Owen et al, 2005).
We investigated 5-HTTLPR in combination with a recently
discovered single nucleotide polymorphism (SNP) with an
A–G substitution (rs25531). Since the SG allele seems to be a
rare variant (Wendland et al, 2006; and was not found in the
present sample at all) several previous reports treated 5-
HTTLPR/rs25531 as a triallelic polymorphism. The LG allele
was reported to behave comparable to the low expressing S
allele (Hu et al, 2005). Furthermore, a recent PET study
demonstrated in vivo that human LA/LA carriers show
higher 5-HTT binding potential in the putamen as an index
of 5-HTT density (Praschak-Rieder et al, in press).
Associations of single polymorphisms with clinically
defined phenotypes suffer from methodological difficulties
(Malhotra and Goldman, 1999) and the heterogeneity and
complexity of clinical phenotypes necessitate large sample
sizes to detect rather small effects. A strategy to overcome
such methodological problems is the endophenotype
approach (Hasler et al, 2004). Hariri et al (2006) suggested
that the examination of regional brain activation during
emotion processing represents an innovative approach to
link neural dysfunction to genes involved in the patho-
genesis of depression with effect sizes 10–20 times larger
than in classical association studies. The amygdala as a
central processor of emotional significance has most
intensively been studied in this emerging field called
‘imaging genetics’. Increased amygdala reactivity is a
frequent finding in major depression (eg Sheline et al,
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2001; Siegle et al, 2007) and a potential neural substrate of
altered emotion processing in patients suffering from
depression (Whalen et al, 2002). Several studies have
demonstrated that healthy S allele carriers show increased
amygdala reactivity to emotional stimuli (Bertolino et al,
2005; Hariri et al, 2002, 2005; Heinz et al, 2005, Pezawas
et al, 2005). Thus, it was speculated that the S allele could
increase the risk for depression via alterations of amygdala
activity during emotion processing (Hariri et al, 2005). In a
recent study, we have demonstrated that depressed patients
carrying 5-HTTLPR risk alleles also show increased
amygdala activity compared with depressed non-risk allele
carriers (Dannlowski et al, in press).
However, all previous studies reporting influence of
genetic variations on brain activity have employed para-
digms using overt stimulus presentation with conscious
processing of emotional stimuli. It remains unclear if the 5-
HTTLPR effect on amygdala activity is restricted to the
conscious level of emotion processing or if it can already be
found at an automatic, pre-attentive stage. According to
neurobiological theories of emotions, the amygdala is
particularly implicated in the rapid and automatic proces-
sing of emotional significance preceding conscious aware-
ness (LeDoux, 1996). In healthy subjects, several studies
have confirmed that the amygdala is engaged during
processing of emotional stimuli, even if presented briefly
(o40 ms) and backward-masked, and thus without con-
scious awareness (eg Whalen et al, 1998). Amygdala
reactivity to covertly but not to overtly presented fear faces
was associated with individual differences in trait anxiety
(Etkin et al, 2004). Thus, using covert stimulus presentation
might be a more appropriate approach to investigate the
role of the amygdala in dispositional emotional reactivity.
So far, however, there has not been any report of a genetic
effect on neural activity to masked emotional stimuli neither
in healthy controls nor in patients with depression.
In the present study, we therefore have investigated
amygdala activity in response to masked displays of
emotional faces in relation to the 5-HTTLPR genotype in
both, a sample of depressed inpatients and healthy subjects.
Success of the masking procedure was assessed by means
of a forced choice detection task. We speculated that 5-
HTTLPR confers a change in amygdala activity at a pre-
attentive stage of emotion processing, at which no
conscious processing of the emotional faces has taken place.
PATIENTS AND METHODS
Subjects
Datasets of 35 inpatients with major depression, diagnosed
with the SCID-I interview (Wittchen et al, 1997), and 32
healthy subjects were analyzed. Sociodemographic and
clinical details of the study groups are shown in Table 1.
Exclusion criteria were neurological abnormalities, sub-
stance abuse, former electroconvulsive therapy, age of 60
and above, and benzodiazepine treatment. Healthy subjects
had no history of psychiatric disorders or psychotropic
medication. All patients were under antidepressant medica-
tion, which was coded in terms of dose and treatment
duration into medication levels from 1 to 4, according to the
suggestions of Sackeim (2001). Details of the antidepressant
medication are listed in Table 2. No patient received lithium
or anti-epileptic drugs. Two patients (both S/LA genotype)
received additional antipsychotic drugs (amisulprid and
quetiapine). Excluding these two patients would not change
the results. The experiments were conducted in accordance
with the Declaration of Helsinki. Approval was obtained
from the ethics committee at the University of Mu¨nster.
After a comprehensive description of the study to the
subjects, written informed consent was obtained.
Genotyping
All subjects were genotyped for the 5-HTTLPR polymorph-
ism, including SNP rs25531 (A/G), according to published
protocols (Deckert et al, 1997; Wendland et al, 2006) with
minor variation. Primers 50-GGCGTTGCCGCTCTGAATGC-
30 and 50-GAGGGACTGAGCTGGACAACCAC-30 (10 pM
each) were used for 20 ml PCR containing 60 ng DNA,
200 mM dNTPs, H2O and 0.5 U HotStar Taq Polymerase with
1.5 mM MgCl2, 1Q-Solution and 1Buffer (Qiagen), with
an initial 15 min denaturation step at 951C followed by 35
PCR cycles of 941C (60 s), 641C (60 s) and 721C (120 s) and a
final extension step of 10 min at 721C. For RFLP analysis
PCR products were digested with HpaII at 371C overnight,
separated in 15% polyacrylamide gels (1TBE, 230 V/cm)
for 3.5 h and visualized by silver staining, which resulted in
fragments between 62 and 340 bp length allowing differ-
entiation and assignment of all 5-HTT-LPR and –rs25531
genotypes. For genotyping quality control about one-third
Table 1 Clinical and Affective Characteristics of Study Participants after Exclusion of Subjects Performing Above Chance in the Detection
Task
Patients (n¼ 28) Controls (n¼ 28) Test statistic (two-tailed)
Age 38.6 (12.2) 36.8 (12.2) t(54)¼ 0.55, NS
Sex (m/f) 10/18 13/15 w2(1)¼ 0.7, p¼ 0.59
5-HTTLPR/rs25531 (LALA/LGLA/SLA/SLG/SS) 7/3/12/1/5 5/3/13/0/7 w
2(4)¼ 1.8, p¼ 0.92
HAMDa 22.2 (3.7) 1.0 (1.2) t(54)¼ 28.6, po0.001
Number of episodes 4.7 (5.3)
Life-time hospitalization (weeks) 7.8 (10.2)
Duration of illness (months) 125.0 (125.5)
aHAMD, Hamilton Rating Scale for Depression (Hamilton, 1960).
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of probands were additionally genotyped by direct auto-
mated sequencing, which resulted in concordance rates of
100%. The genotype distribution of the 5-HTTLPR did not
differ significantly from the expected numbers calculated
according to the Hardy–Weinberg equilibrium. Following
previous studies, subjects were grouped into risk (S) allele
carriers and non-risk (LA) allele carriers for each poly-
morphism. Since the LG and S alleles have comparable levels
of serotonin transporter expression (Hu et al, 2005), the LG
allele was treated as risk allele for the purpose of grouping.
See Table 1, for a description of allele frequencies.
According to t-tests or w2-tests, risk allele carriers and
non-risk allele carriers were not significantly different
concerning age, gender, education, verbal intelligence,
and, for patients, medication level, medication type,
depression severity, duration of illness, number of episodes
or total hospitalization time (all p40.25).
fMRI Methods
Technical details of the fMRI data acquisition and proces-
sing have been reported (Domschke et al, 2006). Briefly,
facial stimuli consisted of sad, angry, happy and neutral
expressions (Ekman and Friesen, 1976). Subjects were
presented with alternating 30 s epochs of a face category
or a no-face stimulus (a grey rectangle). In a passive viewing
task facial stimuli were presented twice per second for 33 ms
in a random sequence directly followed by a 467 ms mask
depicting a neutral face of the same actor. Each emotion
epoch was preceded by a no-face epoch and was presented
twice, resulting in a total presentation time of 8 min. T2*
functional data were acquired at a 3 T scanner (Gyroscan
Intera 3.0T, Philips Medical Systems, Best, NL) using a
single shot echoplanar sequence with parameters selected to
minimize distortion in the amygdala while retaining
adequate S/N and T2* sensitivity according to suggestions
made by Robinson et al (2003). Volumes consisting of 25
axial slices were acquired (matrix 128*128, resolution
1.75*1.75*3.5 mm; TR¼ 3 s, TE¼ 30 ms, FA¼ 901) 160 times
in blocked design, 10 times per condition. To optimize the
following normalization procedures, the same sequence-
parameters were used to cover the whole brain with 43
slices. Additionally, two anatomical data sets were acquired:
T1 weighted inversion recovery and a high resolution T1
weighted 3D sequence (isotropic voxel, 0.5 mm edge length).
Functional imaging data were motion corrected, using a
set of six rigid body transformations determined for each
image, spatially normalized to standard MNI space (Mon-
treal Neurological Institute) with a voxel size of 2*2*2 mm,
and smoothed (Gaussian kernel, 6 mm FWHM) using
Statistical Parametric Mapping (SPM2, Wellcome Depart-
ment of Cognitive Neurology, London, UK). The first
(individual) level analysis was performed by modeling the
different conditions (angry, sad, happy, and neutral) as
variables within the general linear model (modeled with a
standard hemodynamic response function), contrasting
emotional faces (angry, sad and happy) with the neutral
face condition. Voxel values of bilateral amygdala were
extracted, summarized by mean and tested among the
different conditions using the MarsBaR toolbox (Brett et al,
2002). The bilateral amygdala mask was defined according
to a published anatomical atlas, (Tzourio-Mazoyer et al,
2002) which comprised 448 voxels (ie 3.6 ml) and included
the grey nuclei at the rostral boundary of the hippocampus
and the caudal boundary of the uncus.
Repeated measures analysis of variance (ANOVA) was
conducted on mean amygdala activation parameters (con-
trast values). Since left and right amygdala activations were
highly inter-correlated in all three emotion conditions (all
r40.74), an averaged measure for bilateral amygdala
activity was used.
To explore genotype effects in brain regions outside the
amygdala, a voxel-wise approach was employed. The first
level contrast images were included in exploratory second
level group analyses for group and genotype effects. In
addition to the amygdala, the anterior cingulate cortex
(ACC) was treated as region of interest (ROI), since the ACC
has been implicated in the processing of masked emotional
faces in a previous study (Killgore and Yurgelun-Todd,
2004) and was found to activate depending on 5-HTTLR
genotype during emotion processing (Pezawas et al, 2005).
The WFU PickAtlas Toolbox (Maldjian et al, 2003) was used
to create an amygdala/ACC ROI mask for small volume
correction according to the definitions of Tzourio-Mazoyer
et al (2002). The statistical threshold was set at po0.05,
corrected for the amygdala/ACC volume. For the genotype
comparison within each of the two subgroups, a more
lenient threshold of po0.01, uncorrected was chosen.
Outside these anatomical areas with strong a priori
hypothesis, a threshold of po0.05, corrected for the entire
brain was employed.
Detection Task
The detection task was designed to assess possible objective
awareness of the masked emotional faces. After the
experiment, the subjects were informed about the presenta-
tion of covert emotional faces in the MRI scanner. Then
they were asked for subjective awareness of the emotional
prime faces. In the following, the detection task was
administered outside the scanner. Each of the 40 trials
had the following routine: after a fixation cross lasting for
500 ms, a prime face was presented for 33 ms that was
directly followed by a neutral target face. Each prime
Table 2 List of Antidepressant Medication in the Genotype
Groups
5-HTTLPR/5-HT-rs25531










Values reflect number of patients treated with the respective medication.
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emotion (angry, sad, happy and neutral) was presented 10
times and the order of trials was randomized for each
subject. The instruction was to indicate which emotion
quality was displayed briefly as prime. The chance level for
correct answers was 25%. Binominal tests were used to
explore whether a subject performed above chance.
RESULTS
Detection Task
One healthy subject (genotype S/S) reported having
consciously detected brief displays of emotional faces inside
the scanner. This subject also performed above chance in
the detection task (45%, p¼ 0.002). All other participants
reported not having seen any masked emotional faces.
However, three more healthy subjects (S/S, S/LA, and LA/LA)
and seven patients (4 S/LA, S/S, S/LG, and LA/LG) performed
above chance in the detection task. These subjects were
considered ‘aware’ and consequently they were removed
from further analysis. The remaining subjects (28 patients
and 28 controls) performed at or below chance level with no
differences between patients and controls (mean hit
rate¼ 26.4%; range: 12.5–35%). However, inclusion of the
eliminated data would not change the pattern of results.
fMRI Results
Dependent variables were mean amygdala contrast values in
response to masked angry, sad and happy faces versus
neutral faces (Figure 1). A 3 (emotion type: angry, sad,
happy)  2 (group: patients, controls)  2 (genotype: risk,
non-risk) analysis of variance was conducted on the mean
amygdala responses. Box’s test indicated equality of
covariance matrices (Box’s M¼ 33.5, NS) and Mauchly’s
test yielded no violation of the sphericity assumption
(W¼ 0.95, NS). A main effect of 5-HTTLPR genotype was
found, F(1,52)¼ 6.2, p¼ 0.016, Cohen’s d¼ 0.79. As ex-
pected, risk allele carriers (S allele or LG allele carriers,
n¼ 44) demonstrated increased amygdala activity com-
pared with LA/LA homozygotes (n¼ 12, see Figure 2). The
genotype effect was not modulated by group, F(1,52)¼ 0.2,
p¼ 0.6. No other main effect or interaction of emotion type
or group was recorded, although a power analysis with
G-Power (Erdfelder et al, 1996) indicated sufficient power
(0.83) to detect ‘medium’ size interactions (Cohen, 1988). In
addition, the 5-HTTLPR effect was also found in the patient
group alone, F(1,26)¼ 4.4, p¼ 0.046, Cohen’s d¼ 0.92.
However, in the control group, amygdala activity differ-
ences between risk and non-risk allele carriers did not reach
significance, F(1,26)¼ 2.1, p¼ 0.16, Cohen’s d¼ 0.71.
The voxel-wise analysis of the genotype effect in the
whole sample confirmed the ANOVA result of stronger
amygdala responses in risk allele carriers [left amygdala: k
(cluster size)¼ 93 voxels, peak voxel at x¼30, y¼4,
Figure 1 Bar graphs depicting mean amygdala activation to angry, sad and happy facial expressions in comparison to the neutral face condition dependent
on group (patients vs controls) and number of risk alleles (S or LG allele) in the 5-HTTLPR/5-HT-rs25531 polymorphisms.
Figure 2 Coronal view (y¼4) depicting the main effect of 5-HTTLPR/
5-HT-rs25531 on amygdala reactivity. Amygdala reactivity differences are
shown between risk allele carriers (S or LG allele, n¼ 44) and non-risk allele
carriers (LA/LA, n¼ 12) in response to masked negative faces (angry and
sad vs neutral). Voxel threshold was set at po0.05, with FDR (false
discovery rate) correction for bilateral amygdala volume. Cluster maxima
are located at MNI coordinates x¼30, y¼4, z¼14 (left amygdala,
92 voxels, Z¼ 3.60, pcorrected¼ 0.017) and x¼ 30, y¼6, z¼14 (right
amygdala, 41 voxels, Z¼ 3.35, pcorrected¼ 0.024).
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z¼14, Z¼ 3.6, pcorrected¼ 0.024; right amygdala: k¼ 45,
x¼ 30, y¼6, z¼14, Z¼ 3.55, pcorrected¼ 0.024].
Furthermore, a large and highly significant cluster in the
ACC was found [k¼ 854, x¼ 4, y¼ 16, z¼ 26, Z¼ 3.98,
pcorrected¼ 0.001, extending from the supragenual ACC to
the perigenual area, x¼2, y¼ 44, z¼ 2]. The genotype
effect was also found in the patient group alone [left
amygdala: k¼ 35 voxels, x¼30, y¼2, z¼22, Z¼ 3.14,
puncorrected¼ 0.001; right amygdala: k¼ 5, x¼ 28, y¼4,
z¼12, Z¼ 2.61, puncorrected¼ 0.007; ACC: k¼ 91, x¼6,
y¼ 28, z¼ 30, Z¼ 2.88, puncorrected¼ 0.002, extending to
x¼ 4, y¼ 30, z¼2] and in the healthy control group
[right amygdala: k¼ 6, x¼ 30, y¼8, z¼12, Z¼ 2.50,
puncorrected¼ 0.006; ACC: k¼ 175, x¼ 2, y¼ 14, z¼ 28,
Z¼ 3.48, puncorrected¼ 0.001, extending to x¼2, y¼ 50,
z¼ 2]. No genotype effect was detected in brain areas
without a specific a priori hypothesis.
An exploratory analysis of group differences yielded no
significant results in the amygdala/ACC ROI or other brain
areas.
Allele Load
A recent study reported a linear increase of amygdala
responses to overt negative pictures with risk (S) allele load
(Heinz et al, 2005). To explore whether a linear increase of
amygdala activation is responsible for the observed risk vs
non-risk group effect, we conducted a voxel-wise linear
regression analysis of amygdala responses to masked
negative faces in the whole sample. Genotype was coded
as the number of risk alleles (S or LG; 0, 1, or 2). Applying
the same statistical threshold as in the group comparison
(po0.05, corrected for the amygdala/ACC ROI or the entire
brain), no significant effect of allele load was detected,
indicating a ‘dominant’ effect of risk allele carriage.
Amygdala Reactivity and Clinical Characteristics
Amygdala reactivity to any emotion quality was not
significantly associated with number of episodes or dura-
tion of illness, although all correlations carried a positive
sign. However, we observed significant associations of life-
time psychiatric hospitalization and amygdala reactivity to
masked angry (r¼ 0.38, p¼ 0.046), sad (r¼ 0.44, p¼ 0.020)
and happy (r¼ 0.40, p¼ 0.037) expressions. Thus, patients
showing increased amygdala reactivity had a history of
longer previous psychiatric hospitalization. There was no
significant association of amygdala reactivity and current
depressive symptoms (HAMD-score, all ro0.12).
Role of Medication
To explore the role of antidepressant medication, patients
were grouped into a low-dose group (medication level 1–2,
n¼ 12) and a high-dose group (medication level 3–4,
n¼ 16) (Surguladze et al, 2005). High-and low-dose group
did not differ with respect to 5-HTTLPR risk group
(w2(1)¼ 0.0, p¼ 1.0) and amygdala activity elicited by any
masked emotion type (all p40.2). Adding medication level
as covariate did not alter the results.
DISCUSSION
The present data suggest that amygdala reactivity to
emotional faces is modulated by the 5-HTTLPR polymor-
phism even in absence of conscious processing of the
emotional stimuli. These findings replicate and extend the
common observation in healthy subjects that 5-HTTLPR
risk allele carriers demonstrate stronger amygdala activity
in response to emotional faces and pictures (Bertolino et al,
2005; Hariri et al, 2002, 2005; Heinz et al, 2005; Pezawas
et al, 2005). Recently, Smolka et al (2007) reported that the
5-HTTLPR effect on amygdala and anterior cingulate cortex
activity in response to unpleasant pictures is stronger if the
triallelic variant was considered compared with the 5-
HTTLPR effect alone. However, the present study is the first
imaging genetics investigation that used masked displays of
facial expressions and examined patients with clinical
depression. The biasing effect of 5-HTTLPR on amygdala
activity was somewhat more pronounced in the patient
group (although not significantly, as indicated by a non-
significant genotype  group interaction). Furthermore, in
this group, amygdala reactivity was associated with life-time
psychiatric hospitalization, as an index of illness chronicity.
Our data may thus suggest that 5-HTT genotype affects the
course of major depression by biasing amygdala activity
during automatic emotion processing.
Interestingly, the 5-HTTLPR effect was not restricted to
negative (angry and sad) emotions. Masked happy expres-
sions elicited stronger amygdala activity in risk allele
carriers as well, a finding in line with a recent study in
which amygdala activity in a happy face condition was
found to be increased in S allele carriers suffering from
panic disorder (Domschke et al, 2006). In addition, the only
study so far that investigated amygdala activity in response
to masked facial expressions in patients suffering from
major depression demonstrated that unmedicated patients
show increased amygdala activity compared to controls also
for masked happy faces (Sheline et al, 2001). It could be
argued that increased amygdala activity in response to
emotional faces might indicate negatively biased emotion
processing regardless of the stimulus valence, even proces-
sing of happy facial expressions. This corresponds well with
a recent masked affective priming study (Dannlowski et al,
2006). It was found that acutely depressed patients
demonstrate automatic negative evaluative biases elicited
by masked emotional faces, including happy expressions,
which predicted weak therapy outcome. However, since no
evaluation data were collected in the present experiment
this interpretation remains speculative. An alternative
explanation of the observed 5-HTTLPR effect might be that
risk allele carriers are in general more sensitive in the
automatic detection of biologically and socially relevant
information in the environment. There is substantial
evidence that the human amygdala is involved in the
appraisal of events relevant for the survival and well-being
of the organism (O¨hman, 2002; Sander et al, 2003).
According to our data 5-HTTLPR risk allele carriers show
also an enhanced responsivity of the anterior cingulate
cortex to masked facial emotions. The ventral ACC appears
to have an important role in the production of affective
states (Phillips et al, 2003) and in the detection of socially
relevant visual stimuli encountered below the threshold of
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conscious perception (Killgore and Yurgelun-Todd, 2004).
Thus, it can be hypothesized that risk allele carriers might
be more affectively responsive to facial emotions and bring
potentially important stimuli more easily into the forefront
of conscious awareness.
Certain limitations must be acknowledged. Although the
combined sample provided sufficient power to detect main
effects of genotype or interactions, the number of non-risk
allele carriers was small within the two subgroups, limiting
the statistical power to detect genotype effects in the two
groups considered alone. No follow-up data were assessed
and the individual history of stressful life events was not
recorded. Thus, any conclusion with respect to a prognostic
value or causal relationships of genetic susceptibility,
amygdala reactivity and chronification remains speculative.
The correlation analysis of amygdala reactivity and clinical
characteristics was explorative and would not survive alpha
correction for multiple comparisons. Furthermore, we did
not find differences in amygdala activity between depressed
patients and healthy controls. However, all of our patients
were medicated. Hence, even in case of significant group
differences it could not have been concluded whether
any observed group effect was due to depression or a
confounding effect of medication. Nonetheless, our data are
in line with the findings of Sheline et al (2001) and Fu et al
(2004). These previous studies found no differences between
medicated patients and healthy controls with respect to
their amygdala reactivity to emotional faces. Although we
did not find any effect of current antidepressant medication
level on amygdala reactivity or any clinical characteristic in
our patient group, the present data cannot necessarily be
generalized to unmedicated patients. Further studies should
address these issues by investigating unmedicated patients
in longitudinal designs.
In summary, our preliminary findings provide evidence
that genetic susceptibility factors for major depression
might be transported via altered limbic neural activity
already at a preattentive level of emotion processing. The
findings of the present study hopefully stimulate further
investigations of depressed patients employing the imaging
genetics approach. The consistency of previous studies and
the present data underscore the power of direct assessment
of regional brain activity in exploring the functional impact
of genetic variation in clinical states.
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